A RANDOMIZED OPEN-LABEL STUDY OF THE ANTIVIRAL EFFICACY AND SAFETY OF ATAZANAVIR VERSUS LOPINAVIRHHTONAVIR (LPV/RTV), EACH IN COMBINATION WITH TWO NUCLEOSIDES IN SUBJECTS WHO HAVE EXPERIENCED VIROLOGIC FAILURE WITH PRIOR PROTEASE INHIBITOR-CONTAINING HAART REGIIVIEN(S)

Not Applicable

• Conditions: -B23 Human immunodeficiency virus [HIV] disease resulting in other conditions; Human immunodeficiency virus [HIV] disease resulting in other conditions; B23

• Registration Number: PER-001-02
• Lead Sponsor: BRISTOL MYERS SQUIBB PERU S.A.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-01-07
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Subjects will be HlV-infected, wili have failed prior antiretroviral treatment(s) which must have included ene PI, will have a plasma HIV RNA viral load > 1,000 c/mL (Roche Amplicor®) and have a CD4 cell count of > 50 cells/mm3

Exclusion Criteria

Subjects will be excluded if they have prior exposure and reported virologic failure to two or more protease inhibitors (> 30 days of protease inhibitor therapy) and if they have prior use of atazanavir or lopinavir/ritonavir.

Study & Design

• Study Type: Interventional
• Study Design: Not specified